key: cord-0964078-zi48za32
authors: Ryan, Kathryn A; Schewe, Katarzyna E; Crowe, Jonathan; Fotheringham, Susan A; Hall, Yper; Humphreys, Richard; Marriott, Anthony C; Paterson, Jemma; Rayner, Emma; Salguero, Francisco J; Watson, Robert J; Whittaker, Catherine J; Carroll, Miles W; Dibben, Oliver
title: Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology
date: 2021-12-11
journal: J Infect Dis
DOI: 10.1093/infdis/jiab594
sha: 44d40c2c839e54a6c7b58ef36781e9fbe6910391
doc_id: 964078
cord_uid: zi48za32

Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The initial lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract. This study demonstrated that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.

The prospect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-circulation with other respiratory viruses, particularly influenza virus, has raised major concerns over increased stresses to healthcare systems. Data from UK patients during the first COVID-19 wave showed that SARS-CoV-2 and influenza co-infection correlated with greater risk of severe illness and death [1] .

Similar observations were made in rodent models, where sequential influenza and SARS-CoV-2 infection resulted in exacerbated disease pathology [2, 3] .

Influenza vaccination remains of paramount importance in mitigating the risks associated with cocirculation of these viruses, particularly for populations not covered by COVID-19 vaccination programmes.

FluMist/Fluenz live attenuated influenza vaccine (LAIV) is primarily used in children, offering individual protection and reduced community influenza transmission [4] [5] [6] [7] [8] [9] . LAIV can be administered to children with mild fever, cold, or cough, as there is no evidence of LAIV exacerbating pre-existing mild infections [10] [11] [12] [13] [14] [15] . However, the current COVID-19 pandemic raises the possibility of LAIV administration to SARS-CoV-2 infected children displaying either mild or no COVID-19 symptoms [16] [17] [18] . Alternatively, SARS-CoV-2 infection could be acquired following LAIV delivery. Due to the replication-competent nature of LAIV and its intranasal delivery, co-incident LAIV and SARS-CoV-2 replication is feasible. Currently there are no clinical data demonstrating this putative interaction or any impact on the resulting COVID-19 illness in children.

An optimized ferret efficacy model for LAIV was recently described [19] . This study identified the importance of a low, ferret-appropriate vaccine dose in the investigation of LAIV in recapitulating clinical vaccine effectiveness. Ferrets have also been shown to provide a model of COVID-19 disease, with mild clinical signs, consistent lung pathology and upper respiratory tract (URT) shedding of SARS-CoV-2 [20] [21] [22] a surrogate for the mild to moderate disease seen in clinical cases of A c c e p t e d M a n u s c r i p t [23] . Here, combining these approaches we examined the impact of LAIV administration on preexisting SARS-CoV-2 infection and associated respiratory pathology in ferrets. We also evaluated the effect of LAIV given prior to SARS-CoV-2 infection.

In sequentially infected animals, we aimed to assess the impact of LAIV on SARS-CoV-2-related histopathology, SARS-CoV-2 viral levels in tissues and SARS-CoV-2 URT shedding as representative indicators of mild COVID-19 disease [22] . Overall, we intended to understand whether LAIV might exacerbate or ameliorate SARS-CoV-2 infection and disease when delivered before or after challenge.

SARS-CoV-2 strain Victoria/01/2020 [24] was generously provided by The Doherty Institute, Melbourne, Australia at P1 after primary growth in Vero/hSLAM cells and subsequently passaged twice at UK Health Security Agency (UKHSA), Porton in Vero/hSLAM cells (ECACC 04091501) as described previously [22] . were propagated as previously described [19, 25, 26] . LAIV was titrated by Fluorescent Focus Assay (FFA) as previously described [27] . Madin-Darby canine kidney (MDCK) cells used in FFA were obtained from American Type Culture Collection (ATCC) and maintained in Eagle's minimum essential medium with non-essential amino acids at 37°C and 5% CO 2 , as previously described [27] .

A c c e p t e d M a n u s c r i p t Ferrets were confirmed seronegative for circulating H1N1, H3N2, and B viruses by hemagglutination inhibition (HAI) assay and SARS-CoV-2 by ELISA. Ferrets were randomly assigned to study groups.

On Study Day 0 the ferrets were lightly sedated with isoflurane and intranasally challenged with a 1.0 ml (~0.5 ml/naris) dose of SARS-CoV-2. Groups received either mock challenge (phosphate buffered saline, Gibco, cat. 10010023) or SARS-CoV-2 at 6.7 log 10 plaque forming units (PFU)/animal in the same sample diluent. LAIV was administered intranasally under sedation with isoflurane at day -3 or 3 with a single 0.2 ml (~0.1 ml/naris) dose. Groups received either mock vaccination (phosphate buffered saline (ThermoFisher Scientific, Waltham, Massachusetts, USA) with 1x sucrose phosphate (ThermoFisher Scientific: custom product, cat. AC10210390) and 1x gelatine-arginineglutamate (ThermoFisher Scientific: custom product, cat. AC10207676) or LAIV at 4.0 log 10 Fluorescent Focus Units (FFU)/strain/animal, in the same sample diluent.

Throat swabs were taken daily on days 1 to 6 post SARS-CoV-2 challenge. Animals were sedated with isoflurane and a flocked swab (Copan, cat. 552C) was gently stroked across the back of the pharynx in the tonsillar area. 

Lung lobes and NCT were fixed by immersion in 10% neutral-buffered formalin, processed and embedded into paraffin wax. NCT samples were decalcified using an EDTA-based solution prior to embedding. Sections of 4 µm were cut and stained with hematoxylin and eosin (HE) and examined microscopically. A NCT and lung histopathology scoring system was used to evaluate histopathological lesions (Supplementary Table 1 ). Sections were analyzed blinded by 2 qualified veterinary pathologists. In addition, samples were stained using RNAscope to identify SARS-CoV-2 viral RNA. Briefly, tissues were pre-treated with hydrogen peroxide for 10 minutes at room temperature (RT), target retrieval for 15 minutes (98-101°C) and Protease Plus for 30 minutes (40°C) (Advanced Cell Diagnostics). A V-nCoV2019-S probe (Advanced Cell Diagnostics, cat. 848561) was A c c e p t e d M a n u s c r i p t incubated on the tissues for 2 hours at 40°C. Amplification of signal was carried out following the RNAscope protocol using the RNAscope 2.5 HD Detection kit -Red (Advanced Cell Diagnostics).

Digital image analysis was performed on RNAscope labelled slides to ascertain the percentage of stained cells within the lesions, using the Nikon-NIS-Ar package. One section per lung lobe and 2 NCT sections were assessed. NCT sections covered the whole structure.

Throat swab samples were inactivated in AVL (Qiagen) and ethanol. Tissues were homogenized in Buffer RLT+ beta-mercaptoethanol (Qiagen). Homogenate was then centrifuged through a QIAshredder homogenizer (Qiagen) and supplemented with ethanol. Extraction was then performed using the BioSprint™96 One-For-All vet kit (Indical) and Kingfisher Flex platform as per manufacturer's instructions.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) targeting a region of the SARS-CoV-2 nucleocapsid (N) gene was used to determine viral loads and was performed using 

Ferret antiserum (200 μl) was added to 600 μl receptor-destroying enzyme (Deben Diagnostics, Ipswich, UK) and incubated at 37°C for 18-20 hours. The sera were then heat-inactivated at 56°C for 45 minutes. Treated sera were serially diluted 1:2 and added to an equal volume of virus (8 A c c e p t e d M a n u s c r i p t HAU/well). Virus/antibody complexes were incubated at RT for 30-40 minutes before addition of 1 well-volume of 0.5% chicken (H1N1 and B) or guinea pig (H3N2) red blood cell suspension. The resulting mixture was incubated at RT for 60 minutes and HAI endpoints recorded as the reciprocal of the highest dilution of antiserum able to fully prevent agglutination.

Virus in tissues was measured by RT-qPCR at day 6 post-challenge (pc) and the viral loads were expressed as log 10 values. For throat swabs, the geometric mean of RT-qPCR copy numbers for days 1-6 pc was taken for each animal and expressed as a single log 10 value to summarize shedding over time. Statistical analysis was performed in JMP v16.1 (SAS Institute Inc.). Statistical significance is shown on figures by horizontal lines and p-value indicators: ns p>0.05, *p<0.05, **p<0.01, further details of tests applied are given in legends.

To assess the implications of LAIV and SARS-CoV-2 co-infection and its impact on COVID-19 disease severity, SARS-CoV-2 was administered intranasally to groups of 6 or 10 ferrets at 6.7 log 10 Based on previous observations, a period of 6 days post SARS-CoV-2 infection was chosen to enable assessment of both histopathological changes in respiratory tract and SARS-CoV-2 shedding in URT [22] . As shedding of both QLAIV and SARS-CoV-2 have previously been detected at 3 days post-A c c e p t e d M a n u s c r i p t infection [19, 22] , an interval of 3 days between administration of LAIV and SARS-CoV-2 was applied to ensure that the initial virus inoculum was actively replicating at the time of the subsequent infection.

To In the lungs, microscopic inflammatory changes involving both parenchyma and airways were observed in all animals (Supplementary Figure 2) ; all lobes exhibited a multifocal patchy-to-diffuse distribution of lesions. The overall severity of these lesions was low to mid-grade and similar for all 4 groups (Figure 3a and 3b) . No significant differences were observed between lung pathology scores of any of the groups (Figure 3b, Supplementary Table 3) . No SARS-CoV-2 RNA was detected in the lungs of any animal.

The NCT pathology score sums for each animal were compared by study group (Figure 3c Figure 3) . The geometric mean of shedding per day for each group is shown in Figure 4a . In Mock/SARS-CoV-2 animals mean shedding was 4.98 log 10 copies/ml/day. The mean shedding in LAIV primed ferrets (LAIV/SARS-CoV-2) was significantly reduced to 4.08 log 10 copies/ml/day (p=0.0153), while no significant change was noted in SARS-CoV-2/LAIV ferrets (4.43 log 10 copies/ml/day (p=0.37) (Figure 4a) . 

To investigate the effect of LAIV on SARS-CoV-2 replication and pathology we applied the ferret model for mild SARS-CoV-2 clinical disease described previously [22] . Our assessment used the most distinct SARS-CoV-2-related endpoints representing COVID-19 disease: respiratory tract histopathology, SARS-CoV-2 RNA shedding in throat swabs and SARS-CoV-2 viral load in respiratory tissues. Other potential indicators of COVID-19 disease such as fever or weight loss were not observed by Ryan et al. [22] and so were not measured here. For all animals in the SARS-CoV-2 only group (Mock/SARS-CoV-2), microscopic lesions were most prominent in the NCT and comprised acute to sub-acute inflammatory and degenerative changes. Histopathological changes were also seen in the lungs, but with a lower frequency and severity. These findings agreed with previous challenge studies, with less severe pathological changes in the lower respiratory tract compared to the URT [22] . This reflected the mild COVID-19 progression typically seen in children [17, 18] . Mild histopathological changes in lungs and NCT were also noted in animals that received LAIV only (LAIV/Mock). LAIV has an excellent safety profile in clinical studies [10, 15] , suggesting that this level of pathology resulted from LAIV-induced immune responses. While LAIV shedding was not measured here due to variable detection at the low dose applied, successful vaccination was confirmed by seroconversion against B/Phuket/3073/2013 (Supplementary Figure 1) . SARS-CoV-2 RNA was not detected by RT-qPCR in the lungs of any animal, supporting the mild pathology observed and confirming previous reports [22, 31, 33] . In SARS-CoV-2 control animals (Mock/SARS-CoV-2), SARS-CoV-2 RNA was readily detected by RT-qPCR in throat swabs and NCT, confirming previous observations [22] . SARS-CoV-2 RNA was also detected in throat swabs and NCT of co-infected animals (SARS-CoV-2/LAIV and LAIV/SARS-CoV-2). While RNA levels in the SARS-CoV-2/LAIV group were similar to SARS-CoV-2 only controls (Mock/SARS-CoV-2), SARS-CoV-2 shedding was significantly reduced in animals that received LAIV prior to SARS-CoV-2 challenge (LAIV/SARS-CoV-2). Although no significant differences were seen between SARS-CoV-2 RNA levels in NCT by RT-qPCR, a trend for a similar reduction in RNA levels in LAIV/SARS-CoV-2 animals was also evident.

Taken together, these observations aligned with RNAscope observations of NCT, where RNA staining was present in SARS-CoV-2 only (Mock/SARS-CoV-2) and SARS-CoV-2/LAIV groups but not in A c c e p t e d M a n u s c r i p t LAIV/SARS-CoV-2 or LAIV only (LAIV/Mock) groups. The lack of detection of viral RNA by RNAscope in LAIV/SARS-CoV-2 group relative to RT-qPCR was most likely due to the nature of the applied detection methods and sample type. While RT-qPCR of tissue homogenates represents a global measurement, RNAscope provides a highly localized view, potentially resulting in lower overall sensitivity. In addition, RT-qPCR and RNAscope targeted different genes, N and S, respectively. N gene was previously shown to be the most abundant transcript among SARS-CoV-2 genes [34] , which could have influenced detection levels here.

These data suggested that the administration of LAIV did not enhance SARS-CoV-2 replication in ferrets. Moreover, administration of LAIV 3 days prior to SARS-CoV-2 challenge resulted in a reduction in SARS-CoV-2 shedding in the ferret URT. A similar reduction in SARS-CoV-2 shedding in the clinic could have important implications for transmission across the population [35] .

Our findings of reduced SARS-CoV-2 shedding in animals receiving LAIV prior to SARS-CoV-2 align with recent observations in the mouse model, where SARS-CoV-2 viral load in the lungs was significantly reduced following an initial wild-type influenza virus infection, when compared to SARS-CoV-2 only infected animals [2] . However, influenza/SARS-CoV-2 co-infected mice displayed more severe disease despite reduced SARS-CoV-2 viral load [2] . This is contrary to our observations for LAIV, showing no evidence of enhanced lung pathology in LAIV/SARS-CoV-2 co-infected ferrets. This distinction was likely due to the higher pathogenicity of wild-type influenza virus relative to LAIV, paired with a more severe COVID-19 disease model in mice. Also, LAIV, unlike wild-type influenza, does not replicate in ferret lungs, as required by safety testing of commercial vaccine, which further distinguishes our observations from the mouse model [36] .

We hypothesize that viral competition might play a role in the interaction of LAIV and SARS-CoV-2, as well as LAIV-mediated non-specific immune responses. Previously, LAIV was shown to provide non-specific immediate protection against Respiratory Syncytial Virus infection in mice [37] . In another mouse model LAIV achieved immediate, broad-spectrum protection against heterologous A c c e p t e d M a n u s c r i p t influenza strains, mediated by antiviral interferon (IFN) responses and pro-inflammatory cytokines [38] . In clinical observations LAIV was protective against an influenza strain that was antigenically distinct from the vaccine strain, within two weeks of vaccination [39] . Statistical significance is shown by horizontal lines and P-value indicators: ns p > 0.05, *p < 0.05.

Horizontal dotted lines show the lower limit of quantification (LoQ=4.11 log 10 RNA copies/ml/day) and the lower limit of detection (LoD=3.47 log 10 RNA copies/ml/day). Excluding LAIV/Mock, the lower 95% confidence limit of all group means was >LoD. (b) SARS-CoV-2 RNA was measured in nasal A c c e p t e d M a n u s c r i p t cavity tissue homogenates by RT-qPCR. The symbols show the viral load measured in nasal cavity tissue at day 6 for each ferret, bars represent the group mean of 6 ferrets with standard deviation.

LAIV/Mock was treated as a qualitative control only and excluded from statistical analysis, which was by one-way ANOVA only. Comparison lines showing ns p > 0.05 are shown for reference only (no posttest was done). Horizontal dotted lines show the lower limit of quantification (LoQ=4.76 log 10 RNA copies/g) and the lower limit of detection (LoD=4.12 log 10 RNA copies/g). Excluding LAIV/Mock, the lower 95% confidence limit of all group means was >LoD.

Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design

Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of

Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections

Effectiveness of 2 Influenza Vaccines in Nationwide Cohorts of Finnish 2-Year-Old Children in the Seasons

Live attenuated versus inactivated influenza vaccine in infants and young children

Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the

Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study

A pilot study of the effectiveness of a school-based influenza vaccination program

End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom

Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink

Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine)

Live attenuated influenza vaccine use and safety in children and adults with asthma

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines

Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma

Children and SARS-CoV-2 infection: innocent bystanders…until proven otherwise

Prevalence of SARS-CoV-2 Infection in Children Without Symptoms of Coronavirus Disease

Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses

Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

Virological assessment of hospitalized patients with COVID-2019

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia

Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66

Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (flumist) derived from coldadapted a/ann arbor/6/60

Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

SARS-CoV-2 challenge ferret model

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

The coding capacity of SARS-CoV-2

Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients

Evaluation of a coldrecombinant influenza virus vaccine in ferrets

Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine

Immediate and broadspectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t